Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2007

View Archived Issues

Snapshots: studies of vaccines for anthrax, plague, botulinum neurotoxin

Novel therapeutic agents for respiratory disorders described in recent patents

Recent patents disclose novel treatment options for gastrointestinal disorders

LCTA-1246: an anthracyclinone with cytotoxicity against MDR and p53-/- cancer cells

HIV-1 vaccine NYVAC-B safe and immunogenic in phase I study

GSK-364735 well tolerated in double-blind pharmacokinetic study

Studies show feasibility of dapivirine delivery via intravaginal rings

Study suggests HspE7 is effective for carcinoma in situ of the cervix

MVA-nef vaccine shows promise in phase II study

Recent GSK patents impart novel therapeutic agents for substance abuse

Novel TGF-beta type I receptor inhibitor shows potent antitumor activity in murine mesothelioma

SCOLR collaborates with BioCryst on oral formulation of peramivir

Bio-Bridge Science signs collaboration

New insights into novel mechanisms of action of HuMax-EGFr

Apogenix awarded German grant to study APG-101 for spinal cord injuries

TopoTarget in-licenses Zemab

T-705 begins clinical development in U.S. for influenza

Takeda to acquire Paradigm Therapeutics

Depomed seeks clearance to begin phase II studies of Gabapentin GR

Alethia and Biosite to develop antibodies for use in ovarian cancer

Daclizumab meets primary endpoint in phase II relapsing MS study

Outcome of Inflazyme's review of phase IIb asthma findings with IPL-512602

Revised trial design for phase IIb study of bevirimat

Phase II traumatic brain injury trial with anatibant begins enrollment

USAN approves voclosporin as generic name for ISA-247

Antitumor activity seen in phase Ib/II trial of CTCE-9908

Infuse Bone Graft approved for oral maxillofacial and dental regeneration

Tykerb approved in combination with Xeloda for breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...